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Abstract
Multifocal atrial tachycardia (MAT) has a well-known association with Costello syndrome, but is 
rarely described with related RAS/MAPK pathway disorders (RASopathies). We report 11 patients 
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with RASopathies (Costello, Noonan, and Noonan syndrome with multiple lentigines [formerly 
LEOPARD syndrome]) and nonreentrant atrial tachycardias (MAT and ectopic atrial tachycardia) 
demonstrating overlap in cardiac arrhythmia phenotype. Similar overlap is seen in RASopathies 
with respect to skeletal, musculoskeletal and cutaneous abnormalities, dysmorphic facial features, 
and neurodevelopmental deficits. Nonreentrant atrial tachycardias may cause cardiac compromise 
if sinus rhythm is not restored expeditiously. Typical first-line supraventricular tachycardia anti-
arrhythmics (propranolol and digoxin) were generally not effective in restoring or maintaining 
sinus rhythm in this cohort, while flecainide or amiodarone alone or in concert with propranolol 
were effective anti-arrhythmic agents for acute and chronic use. Atrial tachycardia resolved in all 
patients. However, a 4-month-old boy from the cohort was found asystolic (with concurrent 
cellulitis) and a second patient underwent cardiac transplant for heart failure complicated by 
recalcitrant atrial arrhythmia. While propranolol alone frequently failed to convert or maintain 
sinus rhythm, fleccainide or amiodarone, occasionally in combination with propranolol, was 
effective for RASopathy patient treatment for nonreentrant atrial arrhythmia. Our analysis shows 
that RASopathy patients may have nonreentrant atrial tachycardia with and without associated 
cardiac hypertrophy. While nonreentrant arrhythmia has been traditionally associated with 
Costello syndrome, this work provides an expanded view of RASopathy cardiac arrhythmia 
phenotype as we demonstrate mutant proteins throughout this signaling pathway can also give rise 
to ectopic and/or MAT.
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1| INTRODUCTION
The RAS/MAPK signaling pathway performs critical cellular differentiation and 
maintenance functions in a variety of organ systems (Figure 1) (Rauen, 2013; Tidyman & 
Rauen, 2009). Activating mutations in the RAS/MAPK signaling pathway result in a family 
of related disorders termed “RASopathies” that include Costello syndrome (OMIM 
#218040), Noonan syndrome (#163950), Noonan syndrome with multiple lentigines 
(formerly known as LEOPARD syndrome) (#151100), and Cardiofaciocutaneous syndrome 
(#115050). This group of disorders can have overlapping skeletal, dermatologic, 
musculoskeletal, and neurocognitive features. Additionally, individuals with RASopathies 
frequently express similar cardiac phenotypes, encompassing structural and 
electrophysiologic abnormalities. Common cardiac abnormalities seen in RASopathies 
include hypertrophic cardiomyopathy (HCM), valve abnormalities, particularly pulmonic 
valve stenosis, and dysplasia, as well as an increased incidence of atrial and ventricular 
septal defects among others (Lin et al., 2011; Prendiville et al., 2014). While the frequency 
and type of structural cardiovascular abnormalities in RASopathies have been detailed 
elsewhere (Lin et al., 2011; Pandit et al., 2007; Pierpont et al., 2014; Prendiville et al., 2014; 
Rauen et al., 2010; van Berlo, Maillet, & Molkentin, 2013), cardiac electrophysiological 
abnormalities in these syndromes have been less well characterized (Dodo, Gow, Hamilton, 
& Freedom, 1995), with the exception of individuals with Costello syndrome who have been 
Levin et al. Page 2
Am J Med Genet A. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
described with multifocal atrial tachycardia (MAT). Although much progress has been made 
in identifying the genetic causes of heritable arrhythmias, the genetic basis of nonreentrant 
atrial arrhythmias in infants and children is largely unknown. An attempt to identify genes 
that are known to cause triggered activity, and are not already known to cause channelopathy 
(long QT syndrome [LQTS], catecholaminergic polymorphic ventricular tachycardia 
[CPVT], or Brugada Syndrome) or familial atrial fibrillation yields a surprisingly small 
number of genes. Such genes include guanine nucleotide-binding protein inhibiting 
polypeptide (GNAI2, OMIM #192605); and trans-2,3-enoyl-CoA reductase-like protein 
(TERCL, OMIM #617242), which appears to regulate two proteins known to cause CPVT, 
the ryanodine receptor (RYR2, OMIM# 180902) and calsequestrin (CASQ2, 
OMIM#114251) . One gene associated with both ectopic and MAT includes troponin I 
interacting kinase (TNNI3K, OMIM#613932), a kinase that is also thought to affect calcium 
handling, and is associated with a cardiomyopathy phenotype in some instances (Theis et al., 
2014). The only other two genes associated with these arrhythmias identified in OMIM are 
those in the RAS/MAPK pathway (HRAS, KRAS, NRAS, OMIM #190020, OMIM 
#218040).
The purpose of this study is to detail the cardiac electrophysiologic phenotypes and to 
characterize arrhythmia clinical course including treatment seen in individuals with 
RASopathies. We demonstrate that nonreentrant atrial tachycardias, MAT and ectopic atrial 
tachycardia (EAT), can arise from gain-of-function mutations in multiple genes giving rise 
to RAS/MAPK pathway dysregulation. This represents an expanded description of 
RASopathy cardiac phenotype as nonreentrant arrhythmia had previously only been reported 
in Costello syndrome patients. We further show that arrhythmia can occur in the presence or 
absence of cardiac hypertrophy, suggesting that the atrial arrhythmia seen in these patients is 
not simply resulting from hypertrophic cardiomyopathy pressure load. These findings 
provide important clinical information for the diagnosis and management of RASopathy 
patients, and may provide insights into nonreentrant atrial arrhythmia mechanisms.
2| MATERIALS AND METHODS
We retrospectively collected and reviewed the clinical, cardiac, and molecular genetic 
features of patients with a RASopathy who presented with arrhythmia and/or 
cardiomyopathy, and were cared for at six institutions (the Children’s Hospital of 
Philadelphia, A.I. du Pont Hospital for Children, Maine Medical Center, Cincinnati 
Children’s Hospital Medical Center, Children’s Hospital Colorado, and Sanford Children’s 
Hospital) between 2008 and 2013. Two-dimensional echocardiography was performed using 
standard pediatric echocardiographic methods and commercially available machines. 
Segmental anatomy was confirmed and quantitative measures for left ventricular (LV) end 
diastolic dimension (LVeDD), LV end-systolic dimension (LVeSD), interventricular septal 
dimension (IVS) were obtained from m-mode imaging in the parasternal short axis. These 
values were normalized using gender, age, and body surface area resulting in a z-score. 
Echocardiography images and reports were reviewed to evaluate for evidence of congenital 
heart defects, hypertrophic cardiomyopathy, and quantitative wall dimensions. Z-score were 
extracted and displayed in table format. Standard 12 or 15 lead surface electrocardiograms 
with rhythm strips were obtained from each patient and reviewed to confirm arrhythmia 
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diagnosis. Of the nonreentrant tachycardias, we defined MAT (also sometimes described as 
chaotic atrial rhythm, CAR) as a tachyarrhythmia with the following characteristics: (a) 
multiple (at least three) distinct P-wave morphologies; (b) irregular P-P intervals; (c) 
isoelectric baseline between P-waves; and (d) ventricular rate >100 beats/min (Bradley, 
Fischbach, Law, Serwer, & Dick, 2001). EAT is characterized by (a) a P-wave morphology 
during tachycardia that is unique from the sinus P-wave, (b) the P wave of the first beat is 
identical to that of subsequent beats in tachycardia; (c) the cycle length of the first few beats 
may progressively shorten; (d) atrioventricular block can occur in the presence of continuing 
atrial arrhythmia; and (e) ventricular rate >100 beats/min (Bradley et al., 2001; Salerno, 
Anderson, Sharkey, & Iber, 1987) .
All patients had a clinical and molecular diagnosis of a RASopathy syndrome. Molecular 
genetic testing was performed as clinically indicated at the commercial molecular diagnostic 
labs routinely used by each patient’s institution.
3 | RESULTS
Table 1 summarizes the clinical, molecular and cardiac details of 11 patients with 
RASopathies, including two patients with Costello syndrome, Noonan syndrome with 
multiple lentigines (LEOPARD syndrome) (two patients), and Noonan syndrome (seven 
patients).
3.1 | Molecular testing
RASopathy phenotypes are seen in patients with missense mutations in HRAS, BRAF, 
MEK1/2, KRAS, RAF1, PTPN11 (SHP2), SOS1, SHOC2, and CBL, and since the diagnosis 
of the patients in this series, RIT1. These mutations confer a dominant inheritance pattern, 
resulting in gain-of-function mutations or activation of the RAS/MAPK pathway (Figure 1) 
(Pandit et al., 2007; Rauen, 2013; Rodriguez-Viciana et al., 2006; Tartaglia, Cotter, 
Zampino, Gelb, & Rauen, 2003; Tidyman & Rauen, 2009; Wu et al., 2011), with the 
exception of Noonan syndrome with multiple lentigines in which there are dominant 
negative effects from loss-of-function mutations. Each confirmed mutation is listed in Table 
1.
3.2 | Noncardiac clinical features
Table 1 summarizes noncardiac and fetal findings where available. Patients were ascertained 
based on their clinical features. While each syndrome has characteristic clinical features, 
overlap of the clinical features among syndromes is well-recognized, making it difficult to 
predict the molecular defect. This is particularly true among Noonan syndrome patients, 
where mutations in different genes give rise to similar phenotypes (PTPN11, SOS1, RAF1). 
While cardiac findings featured
3.3 | Cardiac clinical features
Arrhythmias were documented from the fetal period to as late as 4 years of age (mean 222 
± 95 days) (Table 1). Presenting rhythms included MAT and EAT. Among those patients 
with MAT, EAT was also noted later in their clinical course. Four of these patients 
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demonstrated supraventricular (reentrant) tachycardia in addition to their nonreentrant atrial 
tachycardia. Ventricular ectopy was present in some individuals.
Figure 2 shows representative rhythm strips from a patient in MAT (Patient 3, Figure 2a) and 
EAT in a different patient (Patient 8, Figure 2b). Identification of multiple P-wave 
morphologies was facilitated by recording the trace at twice the normal sweep speed (50 
mm/s; Figure 2a). By contrast, EAT tracings demonstrate typical findings of two different P-
wave morphologies (one representing sinus rhythm) with irregular RR intervals (Figure 2b). 
In contrast to reentrant supraventricular tachycardia which demonstrates abrupt initiation 
and termination of the abnormal rhythm, intermittent sinus beats can be seen interspersed 
between tachycardia runs in Figure 2b, which is characteristic of EAT.
Each patient had an echocardiogram at the presentation of arrhythmia. Signs of 
cardiomyopathy were present in seven patients, while four patients showed no overt 
evidence of HCM. HCM is typically defined by abnormal wall thickness (Elliott & 
McKenna, 2004; Maron, 2006). Figure 3 provides parasternal short axis images at end-
diastole and end-systole for one patient showing tachycardia without evidence of 
cardiomyopathy (Figure 3a,b, Patient 4) as well as images from one patient who had both 
atrial tachycardia and hypertrophic cardiomyopathy (Figure 3c–f, Patient 8). 
Echocardiographic images from Patient 4 show normal septal (labeled) and posterior left 
ventricular free wall thickness (Figure 3a,b). By contrast, short axis images from Patient 8 
show massive septal hypertrophy that nearly obliterates the left ventricular cavity at end 
systole (Figure 3d). Note that during ventricular filling (end-diastole, Figure 3c) the left 
ventricular volume available for filling is greatly reduced compared to the filling area of the 
nonhypertrophic heart (Figure 3a). Four chamber imaging of Patient 8 demonstrates the 
ventricular septum protruding into the left ventricular outflow tract (Figure 3e,f) and 
companion Doppler flow imaging shows mid left ventricular cavity flow acceleration which 
defines a subset hypertrophic cardiomyopathy.
Quantitative echocardiographic data were available for eleven patients (Table 1) including 
LVeDD (z-score range: −3.84 to 2.77), LVeSD (z-score range: −5.02 to 5.32), and LV 
shortening fraction (range: 38.9 to 66%). Left ventricular mass z-score was available for 10 
of 11 patients and ranged from −3.27 to +9.42. No patient had complex congenital heart 
disease, but septal defects were detected in three patients. In addition, six patients 
demonstrated valvar pulmonary stenosis, which was severe in one patient. No other 
hemodynamically significant congenital heart defects were diagnosed.
3.4 | Arrhythmia treatment
Patients presenting in the neonatal period often had mild hemodynamic compromise and 
poor feeding over time prior to restoration of sinus rhythm. Initial medical therapies 
included propranolol in 10 patients. Treatment with propranolol alone and/or with digoxin 
failed to maintain sinus rhythm in all but one patient (Table 1). Flecainide alone or in 
combination with propranolol was the most common chronic anti-arrhythmic treatment 
chosen. Amiodarone alone was used successfully for two patients, although one patient 
subsequently transitioned to propranolol and verapamil due to amiodarone toxicity. Anti-
arrhythmic agents were successfully weaned in all patients, except for one who died from 
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complications of a rhabdomyosarcoma and a second who underwent cardiac transplantation, 
in part because of functional hemodynamic instability that was compounded by rhythm 
disturbance despite flecainide treatment. In the 10 patients whose clinical arrhythmias 
resolved, medications were discontinued at a mean age of 28.0 months (range 6.5–49 
months). A third child from our cohort died from complications of cardiac surgery (septal 
myomectomy). This child’s arrhythmia resolved prior to surgery, so this case was not 
considered an anti-arrhythmic treatment failure. A 4-month-old child with cellulitis 
apparently died of complications of systemic infection, unrelated to arrhythmia.
4 | DISCUSSION
This multi-institutional case series illustrates an association between mutations in RAS/
MAPK signaling pathway genes and nonreentrant atrial tachycardia (MAT and EAT). 
Importantly, rhythm disturbances occurred both in the presence and absence of cardiac 
hypertrophy. We observed predominantly nonreentrant atrial tachycardia in our cohort (i.e., 
EAT and MAT, which is also known as CAT). Reportedly, 84% of atrial arrhythmias in 
children arise from reentrant circuits involving accessory pathways (Ko, JK, BJ, Strasburger, 
and Benson DW jr., 1992). In contrast, in our cohort, we observed nonreentrant atrial 
arrhythmias, which had previously been identified only in Costello syndrome patients (Lin et 
al., 2011).
Distinguishing between reentrant and nonreentrant arrhythmias can be critically important as 
therapies and prognoses differ greatly between these two entities. Propranolol and digoxin 
continue to be the preferred first line treatment for reentrant arrhythmias. However, we 
found that infants with RASopathies and atrial tachycardia can be difficult to manage, 
partially because propranolol and digoxin fail to convert or maintain sinus rhythm in patients 
with MAT and EAT. By contrast, in this cohort, effective medications included flecainide 
alone, flecainide in combination with propranolol, or amiodarone alone. While propranolol 
can be used to treat EAT effectively in other patient populations, it is not immediately clear 
why this drug is less effective in this subgroup of patients. Importantly, arrhythmia resolved 
or was well-controlled in all but two cases. The former were successfully weaned off anti-
arrhythmic medications after a period ranging from 6.5 to 49 months. The latter group 
included a 4 months old boy who was found pulseless and unresponsive during inpatient 
cellulitis treatment and died from an unclear etiology and another patient who underwent 
cardiac transplantation. This second patient had poorly tolerated break-through tachycardia 
in the context of worsening left ventricular outflow obstruction. While an atrial arrhythmia 
episode would not be predicted to cause catastrophic hemodynamic compromise, we cannot 
exclude the possibility that atrial arrhythmia complicated this boy’s death.
While flecainide, a sodium channel blocker, has been used successfully to treat ectopic or 
MAT for over 20 years (Houyel, Fournier, & Davignon, 1990), the mechanism of its efficacy 
is not immediately obvious and remains controversial (Bannister et al., 2015; Hilliard et al., 
2010; Smith & Macquaide, 2015; Watanabe et al., 2009). Previous studies suggested that 
MAT and EAT result from disrupted calcium homeostasis leading to triggered activity 
(Levine, Michael, & Guarnieri, 1985; Marchlinski & Miller, 1985). Flecainide, by contrast, 
is traditionally classified as a sodium channel blocker (Vaughan Williams, 1975), and 
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sodium channel blockers would not be expected to affect calcium homeostasis directly. 
Importantly, it has been argued that flecainide diminishes calcium release from the 
sarcoplasmic reticulum through ryanodine receptors in addition to its direct inhibitory action 
on sodium channels (Bannister et al., 2015; Mehra, Imtiaz, van Helden, Knollmann, & 
Laver, 2014; Smith & Macquaide, 2015; Watanabe et al., 2009). Again, nonreentrant 
arrhythmias arise secondary to dysregulated calcium release, such as inappropriate calcium 
release from the sarcoplasmic reticulum through the ryanodine receptor. While it is difficult 
to imagine how direct sodium channel blockade would diminish sarcoplasmic reticulum 
calcium release and treat nonreentrant arrhythmias, perhaps flecainide’s direct or indirect 
action on the ryanodine receptor accounts for the drug’s efficacy in treating MAT and EAT. 
The fact that flecainide, a drug used to restore calcium homeostasis, is an effective anti-
arrhythmic for MAT and EAT in RASopathy patients suggests that disordered calcium 
release may result directly from RASopathy mutation expression.
In addition to increased arrhythmogenesis, disordered calcium handling can contribute to 
cardiomyopathy and heart failure (Anastasaki, Estep, Marais, Rauen, & Patton, 2009; Lan et 
al., 2013). Incessant atrial arrhythmias may cause cardiomyopathy and diminished 
cardiovascular function. Conversely, arrhythmias may be secondary to the pressure load 
conferred by a cardiomyopathy. Finally, the presence of cardiomyopathy prior to arrhythmia 
might suggest that nonreentrant atrial tachycardia is secondary to elevated end-diastolic 
pressure subsequent to cardiomyopathy (pressure load). In this retrospective case series, we 
found that 4 (36%) of 11 patients presenting with nonreentrant atrial tachycardia had no 
evidence of cardiomyopathy as indicated by increased wall thickness. Thus, at least some 
atrial tachycardia in our cohort did not arise secondary to pressure overload, again 
suggesting disordered calcium release arises as a result of some other mechanism.
Hypertrophic cardiomyopathy is defined by abnormal wall thickness (Elliott & McKenna, 
2004; Maron, 2006; McNally, Barefield, & Puckelwartz, 2015). Seven (64%) of our 11 
patients demonstrated cardiac hypertrophy, meeting American Heart Association criteria for 
hypertrophic cardiomyopathy. Four of the seven with hypertrophy demonstrated asymmetric 
septal hypertrophy. While 4 of 11 (36%) patients did not meet traditional criteria for 
diagnosing hypertrophic cardiomyopathy, despite repeated episodes of atrial tachycardia, 
they had elevated shortening fractions (Patient 1: 39%; Patient 4: 42%; Patient 7: 56%; 
Patient 10: 46%). This increased shortening fraction suggests that these patients have 
elevated intracellular calcium concentrations since there is a strong dependence between 
intracellular calcium concentration and myocyte contraction force (Kentish, ter Keurs, 
Ricciardi, Bucx, & Noble, 1986; Sun & Irving, 2010).
Thus, several observations suggest that RASopathy patients exhibit calcium dysregulation 
that can give rise to cardiomyopathy and/or atrial tachycardia. First, RASopathy patients 
demonstrate MAT and EAT thought to be initiated by triggered activity (Bradley et al., 2001; 
Marchlinski & Miller, 1985; McCord & Borzak, 1998). Furthermore, triggered activity is 
caused by disordered calcium homeostasis, that frequently results from inappropriate 
calcium release from ryanodine receptors (Wehrens et al., 2004). Medications diminishing 
ryanodine receptor calcium release, such as flecainide, have been particularly effective in 
treating RASopathy patients with MAT or EAT, suggesting that restoring calcium 
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homeostasis by decreasing calcium release results in decreased triggered activity and 
diminished arrhythmia. Finally, increased shortening fraction is consistent with increased 
calcium release from intracellular stores and those RASopathy patients not showing overt 
cardiomyopathy demonstrate hyper-contractile shortening fractions. These observations may 
provide the basis for testable hypotheses directed at understanding RASopathy cardiac 
pathology. Such testing could include expression of RASopathy-causing mutations in animal 
models or patient derived induced pluripotent stem cells (iPSC) and quantifying intracellular 
calcium content or numbers of calcium release events in models versus controls.
The current study is limited by its small patient numbers. Given the relatively rare 
occurrence of non-Noonan syndrome RASopathies, we pooled patients from a multi-
institutional network. Although Cardiofaciocutaneous syndrome was not represented in this 
series, it is likely that nonreentrant tachycardia will be observed. Further work to verify our 
observations in a larger cohort should be performed, ideally in a prospective manner. 
Additional studies using animal models or patient-specific expression systems should be 
used to test the hypotheses raised here. This would be an important first step in deepening 
our understanding of RASopathy cardiac disease mechanisms and could ultimately lead to 
the identification and development of novel therapeutics for patients with RASopathies.
In conclusion, we report that patients with RAS/MAPK pathway mutations have 
nonreentrant atrial tachycardia that is poorly treated by propranolol or digoxin (typical first-
line SVT treatments), but responds well to flecainide or amiodarone alone or in concert with 
propranolol. Atrial tachycardia in RASopathy patients occurred in the presence and absence 
of hypertrophic cardiomyopathy. Those patients with nonreentrant tachycardia without 
hypertrophic cardiomyopathy frequently demonstrated hyper-dynamic function as evidenced 
by increased shortening fraction, suggesting that they possessed increased intracellular 
calcium. Nonreentrant tachycardia resolved in 9 of 11 patients. In addition to providing 
insights that will aid management of patients with a RASopathy, the clinical findings here 
suggest the hypothesis that activating RAS/ MAPK pathway mutations result in intracellular 
calcium dysregulation that leads to either arrhythmia, cardiac hypertrophy, or both. There is 
a need for additional investigation and longitudinal study in this patient population to define 
evidence based guidelines for cardiac surveillance, but, in the interim, contributing authors 
have suggested collaborative expert opinion consensus statements may also be useful. 
Toward this end, we would suggest raising suspicion for arrhythmia and cardiomyopathy in 
neonatal RASopathy patients. Respiratory distress, diminished feeding tolerance, or 
unexplained irritability should suggest cardiac evaluation, including ECG, echocardiogram 
and 24 hr ambulatory ECG monitoring. In addition to typical signs and symptoms of 
arrhythmia or cardiomyopathy, evidence of hyperdynamic cardiac function seen on 
echocardiogram should also raise suspicion for arrhythmia, cardiomyopathy or nascent 
cardiomyopathy as this was present in some study patients with arrhythmia prior to overt 
chamber dimension abnormalities. This case series should increase awareness among 
pediatric cardiologists and geneticists about these increasingly recognized syndromes and 
provide clinical information assisting the diagnosis and management of cardiac disease, and, 
ultimately promote understanding of the molecular mechanisms underlying these diseases.
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FIGURE 1. 
The RAS/mitogen-activated protein kinase (MAPK) signaling pathway and associated 
developmental syndromes (indicated by dashed lines). The MAPK signaling pathway of 
protein kinases is critically involved in cell proliferation, differentiation, motility, apoptosis, 
and senescence. The RAS/MAPK pathway proteins with germline mutations in their 
respective genes are associated with Noonan (NS), Noonan syndrome with multiple 
lentigines (NSML)(LEOPARD), neurofibromatosis, type 1 (NF1), capillary malformation–
arteriovenous malformation (CM-AVM) due to RAS1 mutations, Costello (CS), 
Cardiofaciocutaneous (CFC) and Legius syndromes. Figure reprinted from Rauen (2013) 
with permission from Elsevier. [Color figure can be viewed at wileyonlinelibrary.com]
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FIGURE 2. 
Rhythm strips showing multi-focal atrial tachycardia and ectopic atrial tachycardia (a) 12 
lead rhythm strip from Patient 3 recorded at sweep speeds of both 25 and 50 mm/s 
demonstrating multifocal atrial tachycardia with at least five different P-wave morphologies 
(labeled P1 to P5). Note how the increased sweep speed (50 mm/s) facilitates diagnosis 
when compared to the portion recorded at the standard sweep speed (25 mm/s). (b) Rhythm 
strip from patient 8 demonstrating episodes of sinus rhythm (denoted by black bar) followed 
by intermittent episodes of ectopic atrial tachycardia (red bar). In contrast to the tracing from 
(a), P-wave morphology, axis and amplitude are roughly the same. Unlike reentrant 
arrhythmias, patients may quickly enter and exit atrial tachycardia and have sinus beats 
interspersed between nonsinus beats as seen here. [Color figure can be viewed at 
wileyonlinelibrary.com]
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FIGURE 3. 
Parasternal short axis echocardiographic images from RASopathy patients presenting with 
nonreentrant atrial tachycardia showing ventricular wall dimensions at both end-diastole (a, 
c), and end-systole (b, d), for patient 4 (a, b), patient 8 (c–f). Note that images from patient 4 
show normal septal and free wall thickness, while those images from patient 8 show 
hypertrophied septum and myocardium, with muscle nearly obliterating the LV cavity at end 
systole in patient 8. Four chamber imaging from patient 8 demonstrates left ventricular 
outflow tract obstruction (e) and Doppler flow imaging of the identical region shows mid-
cavitary flow acceleration (f). [Color figure can be viewed at wileyonlinelibrary.com] 
prominently in the clinical presentation, a number of distinct phenotypic features prompted 
testing for RAS/MAPK disorders (Table 1). Postnatally, hyper-pigmented macules and 
dysmorphic craniofacial features prompted molecular testing with increased suspicion for 
RASopathy. Additional features suggesting RASopathies included down slanted palpebral 
fissures, wide nasal root with flat bridge, low set dysmorphic ears, and coarse facial features.
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